Back to Interventions
Substance / Medication

Diethylcarbamazine

SNOMED 387340001UMLS C0012191

Overview

Active Ingredient
diethylcarbamazine
RxNorm CUI
3384

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Infection by Loa loa
Pulmonary infiltrates with eosinophilia

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

13 trials linked to this intervention

13
Total Trials
5
Recruiting
4
With Results

Recent Trials

The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia

NCT00632554Phase 4Completed50 enrolled

Small Particle Steroids in Refractory Asthma

NCT01171365Phase 4Completed30 enrolled

Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients

NCT02654145Phase 4Completed145 enrolled

Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma

NCT03610685Phase 4Completed33 enrolled

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

NCT03953300Phase 4Active Not Recruiting75 enrolled
View all 13 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Diethylcarbamazine (DEC)-medicated salt for community-based control of lymphatic filariasis.
Adinarayanan S, Critchley J, Das P K et al. · Cochrane Database Syst Rev · 2007
PMID: 17253495Meta-AnalysisFull text (PMC)
Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti.
de Kraker Marlieke E A, Stolk Wilma A, van Oortmarssen Gerrit J et al. · Trop Med Int Health · 2006
PMID: 16640625Meta-Analysis
Impact of mass drug administration with ivermectin, diethylcarbamazine, and albendazole for lymphatic filariasis on hookworm and Strongyloides stercoralis infections in Papua New Guinea.
Tobon Ramos Jannet A, Maure Tobias, Carias Lenore et al. · PLoS Negl Trop Dis · 2025
PMID: 40063867RCTFull text (PMC)
A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis.
Opoku Nicholas O, Doe Felix, Dubben Bettina et al. · PLoS Negl Trop Dis · 2023
PMID: 37205721RCTFull text (PMC)
Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial.
Laman Moses, Tavul Livingstone, Karl Stephan et al. · Lancet Infect Dis · 2022
PMID: 35533701RCTFull text (PMC)
A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa loa Infection.
Legrand Fanny, Herrick Jesica, Makiya Michelle et al. · Clin Infect Dis · 2021
PMID: 32910141RCTFull text (PMC)
An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.
Jambulingam Purushothaman, Kuttiatt Vijesh Sreedhar, Krishnamoorthy Kaliannagounder et al. · PLoS Negl Trop Dis · 2021
PMID: 33591979RCTFull text (PMC)
Heterogeneous response of Wuchereria bancrofti-infected persons to diethylcarbamazine (DEC) and its implications for the Global Programme to Eliminate Lymphatic Filariasis (GPELF).
Sankari Thirumal, Subramanian Swaminathan, Hoti Subhash L et al. · Parasitol Res · 2021
PMID: 33146778RCT
Individual Efficacy and Community Impact of Ivermectin, Diethylcarbamazine, and Albendazole Mass Drug Administration for Lymphatic Filariasis Control in Fiji: A Cluster Randomized Trial.
Hardy Myra, Samuela Josaia, Kama Mike et al. · Clin Infect Dis · 2021
PMID: 33728462RCT
Posttreatment Reactions After Single-Dose Diethylcarbamazine or Ivermectin in Subjects With Loa loa Infection.
Herrick Jesica A, Legrand Fanny, Gounoue Raceline et al. · Clin Infect Dis · 2017
PMID: 28329346RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Diethylcarbamazine (substance)
SNOMED CT
387340001
UMLS CUI
C0012191
RxNorm CUI
3384

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
13
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.